Curated News
By: NewsRamp Editorial Staff
November 13, 2026
Annovis Bio Reports Q3 2026 Progress on Alzheimer’s and Parkinson’s Trials
TLDR
- Annovis Bio's fully enrolled 862-patient Phase 3 DUET-AD trial with dual readouts positions ANVS ahead of rivals in the Alzheimer's race.
- Buntanetap inhibits translation of neurotoxic proteins via RNA targeting, with two efficacy readouts at six and 18 months.
- Annovis Bio's buntanetap could halt neurodegeneration and improve cognition for Alzheimer's and Parkinson's patients, offering hope for better tomorrows.
- Annovis Bio raised $21 million, including $5 million from its chairman, to fund operations through the March 2027 topline data readout.
Impact - Why it Matters
The news matters because it signals that Annovis Bio is advancing a potential disease-modifying therapy for Alzheimer’s and Parkinson’s diseases, which affect millions worldwide. With the DUET-AD trial fully enrolled and topline data expected in March 2027, investors and patients are closer to understanding whether buntanetap can slow or halt neurodegeneration. The successful completion of a $21 million financing and partnership with Weave Bio further de-risks the regulatory path, potentially bringing a new oral treatment option to market. For patients and families, this represents hope for a therapy that targets underlying causes rather than just symptoms.
Summary
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, has provided third-quarter 2026 corporate updates on its lead drug candidate buntanetap for Alzheimer’s and Parkinson’s diseases. The company’s pivotal Phase 3 DUET-AD trial is fully enrolled with 862 patients with early Alzheimer’s disease and features two prespecified efficacy readouts at six and 18 months to evaluate symptomatic and disease-modifying effects, respectively. Annovis expects topline results from the six-month treatment period in March 2027 and plans to begin transitioning eligible patients into its Alzheimer’s open-label extension study by the end of November 2026. Additionally, the company reported enrollment of 326 patients in its Parkinson’s disease open-label extension study, which is designed to evaluate the long-term safety and efficacy of buntanetap over 36 months.
In September, Annovis partnered with Weave Bio to support regulatory documentation and preparation of its planned New Drug Application (NDA). The company subsequently closed an approximately $21 million underwritten public offering on Nov. 6, 2026, including a $5 million investment from its board chairman. Management said the financing is expected to support operations through the anticipated March 2027 topline data readout. To view the full press release, visit https://ibn.fm/6c61g. Headquartered in Malvern, Pennsylvania, Annovis Bio is developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio Reports Q3 2026 Progress on Alzheimer’s and Parkinson’s Trials
